WBB Securities reissued their buy rating on shares of Omeros Corporation (NASDAQ:OMER) in a report published on Thursday morning. They currently have a $75.00 price objective on the biopharmaceutical company’s stock.

Other research analysts also recently issued research reports about the stock. S&P Equity Research lifted their price target on shares of Omeros Corporation from $7.65 to $8.63 in a research note on Monday, October 17th. Needham & Company LLC decreased their price target on shares of Omeros Corporation from $28.00 to $24.00 and set a buy rating for the company in a research note on Thursday, November 10th. Maxim Group set a $19.00 price target on shares of Omeros Corporation and gave the stock a buy rating in a research note on Wednesday, November 2nd. Cantor Fitzgerald reiterated a buy rating and issued a $21.00 price target on shares of Omeros Corporation in a research note on Wednesday, August 10th. Finally, FBR & Co reiterated a buy rating on shares of Omeros Corporation in a research note on Thursday, November 10th. One investment analyst has rated the stock with a sell rating and six have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $33.23.

Analyst Recommendations for Omeros Corporation (NASDAQ:OMER)

Omeros Corporation (NASDAQ:OMER) traded down 0.45% during midday trading on Thursday, hitting $13.18. 192,974 shares of the stock traded hands. The firm’s market cap is $565.62 million. Omeros Corporation has a 12-month low of $7.20 and a 12-month high of $16.80. The company’s 50-day moving average is $9.57 and its 200 day moving average is $10.86.

Omeros Corporation (NASDAQ:OMER) last issued its quarterly earnings results on Wednesday, November 9th. The biopharmaceutical company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.06. The firm earned $11.30 million during the quarter, compared to analysts’ expectations of $11.64 million. During the same quarter in the prior year, the firm earned ($0.53) EPS. The firm’s revenue was up 253.1% compared to the same quarter last year. On average, analysts anticipate that Omeros Corporation will post ($1.63) EPS for the current fiscal year.

In related news, VP Marcia S. Kelbon sold 16,000 shares of the stock in a transaction that occurred on Thursday, September 15th. The stock was sold at an average price of $10.91, for a total transaction of $174,560.00. Following the sale, the vice president now owns 179,597 shares of the company’s stock, valued at $1,959,403.27. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 13.60% of the company’s stock.

Several large investors have recently added to or reduced their stakes in OMER. BlackRock Advisors LLC increased its stake in Omeros Corporation by 1.0% in the second quarter. BlackRock Advisors LLC now owns 17,415 shares of the biopharmaceutical company’s stock valued at $183,000 after buying an additional 173 shares during the period. State Board of Administration of Florida Retirement System increased its stake in Omeros Corporation by 1.2% in the second quarter. State Board of Administration of Florida Retirement System now owns 30,737 shares of the biopharmaceutical company’s stock valued at $323,000 after buying an additional 351 shares during the period. BlackRock Group LTD increased its stake in Omeros Corporation by 4.5% in the third quarter. BlackRock Group LTD now owns 12,440 shares of the biopharmaceutical company’s stock valued at $139,000 after buying an additional 540 shares during the period. Nationwide Fund Advisors increased its stake in Omeros Corporation by 0.9% in the second quarter. Nationwide Fund Advisors now owns 67,255 shares of the biopharmaceutical company’s stock valued at $708,000 after buying an additional 631 shares during the period. Finally, Gradient Investments LLC increased its stake in Omeros Corporation by 3.3% in the third quarter. Gradient Investments LLC now owns 25,285 shares of the biopharmaceutical company’s stock valued at $282,000 after buying an additional 814 shares during the period. 51.86% of the stock is currently owned by institutional investors.

Omeros Corporation Company Profile

Omeros Corporation is a biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. The Company’s marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens replacement.

5 Day Chart for NASDAQ:OMER

Receive News & Stock Ratings for Omeros Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros Corporation and related stocks with our FREE daily email newsletter.